Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERROCLEAR study of vamifeport in HFE-related hereditary hemochromatosis
2025-523793-16-00Phase 2Authorised
- Sponsor
- CSL Behring
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in Hereditary hemochromatosis type 1 comparing Vamifeport with Placebo (2 arms). Primary endpoint: Change from baseline in MRI-based liver iron concentration. Planned start Jul 2026; status: authorised.
02
Drugs
vamifeport
03
Conditions
Hereditary hemochromatosis type 1
Beyond the preview
Go deeper on 2025-523793-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523793-16-00.